Conference Presentations

PharmaSUG: A TransCelerate Initiative – How Can You Modernize Your Statistical Environment? (May 2021)

SCOPE Summit: Statistical Programming Demystified (February 2016) – Invited Speaker for CHI’s Clinical Research Statistics for Non-statisticians.

Semi-Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference: Staying Abreast of Updated Clinical Data Management Standards (October 2015) – Q1 Productions – Invited Speaker.

SCOPE Summit: Doing More, Faster, Better! How CDISC Data Standards Shorten the Clinical Trial Life Cycle Across the Globe (February 2015) – Invited Speaker for CHI’s Electronic Data in Clinical Trials Conference.

Clinical Data Standards & Transparency Conference: Going Global – How Data Standards Can Improve the Management of Trial Data Across Borders (July 2014) – Invited Speaker for CBI Net.

Pharmaceutical SAS User Group (PharmaSUG) Conference: The New Tradition: SAS® Clinical Data Integration (June 2014) – Applications Development Section.

North East SAS Users Group (NESUG) Conference: Using SAS® Metadata as a Key Performance Indicator (September 2013) – Invited Speaker for Management and Administration Section. Also, presented as an invited speaker at Clinical Data Analytics (July 2013).

Pharmaceutical SAS User Group (PharmaSUG) Conference: The Y2K17 Bug! Responding to PDUFA Requirements through a Metadata System (May 2013) – Data Standards Section.

Pharmaceutical SAS User Group (PharmaSUG) 2012 Conference: Could Have, Would Have, Should Have! Adopting Good Programming Standards, Not Practices, to Survive an Audit! (May 2012) – Best Paper for Industry Basics Section. Also, presented at Denver SAS User Group (October 2012).

SAS User Group 30: Using Procedure-Based ODS Data Components in Statistical Reporting (March 2005. Also, presented at Pharmaceutical SAS User Group 25 (June 2005)

Publications & Presentations

Journal Publications

Amoruccio VJ, Mital DP, Srinivasan S. A Risk Score to Evaluate the Risk of Lung Cancer in People with HIV. Journal of Cancer Clinical Trials. Volume 6:3, 2021. (PDF)

Schram, A. M., Subbiah, V., Sullivan, R., Cosman, R., Liu, J., Sbar, E. I., Hoang, T., Chen, J., Johnson, M., Amoruccio, V., Shearer, T., Kamal, A., Lewis, J., Shao, W., Edris, B., Luo, L., & Desai, J. Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors. Cancer Research.

Vincenzi, B., Bui, N., Dileo, P., Federman, N., Riedel, R. F., Van Tine, B. A., Amoruccio, V., Lim, A., Oton, A. B., & Kasper, B. (2024). Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study. J Clin Oncol. 2024;42(16_suppl):11556.

Kasper, B., Federman, N., Reichardt, P., Attia, S., Lim, A., Amoruccio, V., Cho, S., & Riedel, R. F. (2024). Efficacy and safety of nirogacestat in patients with desmoid tumor and adenomatous polyposis coli (APC) mutation: Phase 3 DeFi analyses. J Clin Oncol. 2024;42(16_suppl):11558. doi:10.1200/JCO.2024.42.16_suppl.11558

​Kasper, B., Federman, N., Reichardt, P., Riedel, R. F., Lim, A., Amoruccio, V., Cho, S., & Van Tine, B. A. (2024). Descriptive evaluation of patients with desmoid tumor and co-occurring somatic mutations of CTNNB1 and APC in the phase 3 DeFi trial [Poster presentation P 33]. Connective Tissue Oncology Society 2024 Annual Meeting, Miami, FL.

Stacchiotti, S., Chawla, S. P., Chugh, R., D'Amato, G., Gounder, M., Ratan, R., van der Graaf, W. T. A., Amoruccio, V., Bell, T., Cho, S., & Schöffski, P. (2024). Impact of nirogacestat (niro) on patient-reported outcomes (PROs) in adults with desmoid tumor with a best overall response (BOR) of stable disease (SD): Post hoc analysis from the DeFi study. ESMO Open. 2024;9:102447. doi:10.1016/j.esmoop.2024.102447​

Dolan SM, Gross SJ, Merkatz IR, Amoruccio V*, Sullivan LM, Malone FD, Porter TF, Nyberg DA, Comstock CH, Hankins GD, Eddleman K, Dugoff L, Craigo SD, Timor-Tritsch I, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME. The contribution of birth defects to preterm birth and low birth weight. Obstet Gynecol. 2007 Aug;110(2 Pt 1):318-24. doi: 10.1097/01.AOG.0000275264.78506.63. PMID: 17666606.

Paasche-Orlow MK, Cheng DM, Palepu A, Meli S, Amoruccio V*, Samet JH. Health literacy, antiretroviral adherence, and HIV-RNA suppression: a longitudinal perspective. J Gen Intern Med. 2006 Aug;21(8):835-40. doi: 10.1111/j.1525-1497.2006.00527.x. PMID: 16881943; PMCID: PMC1831568.

Dugoff, L; Hobbins, J; Amoruccio, V*; Malone, F; Belfort, M; Nyberg, D; Comstock, C; Bukowski, R; Eddleman, K; Gross, S; Craigo, S; Timor, I; Carr, S; Wolfe, H; D'alton, M. “First trimester uterine artery Doppler and subsequent intrauterine growth restriction and preterm birth”; American Journal of Obstetrics and Gynecology (OB); December 2004, Supplement • Volume 191 • Number 6 • pS22 to pS22

Dugoff, L; Amoruccio, V*; Hobbins, J; Malone, F; Canick, J; Porter, F; Luthy, D; Comstock, C; Bukowski, R; Eddleman, K; Gross, S; Craigo, S; Timor-Trisch, I; Carr, S; Wolfe, H; D'alton, M; “The effect of vaginal bleeding on maternal serum PAPP-A, free [beta] -hCG, and nuchal translucency. A population based screening study (the FASTER trial)”; American Journal of Obstetrics and Gynecology (OB); December 2004, Supplement • Volume 191 • Number 6 • pS47 to pS47

*Published as Vincent Faber aka Vincent Amoruccio